Coming of age: the artificial pancreas for type 1 diabetes

Diabetologia

Volumn 59, Issue 9, 2016, Pages 1795-1805

  Thabit, Hood ^a,b   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Artificial pancreas; Closed loop system; Continuous glucose monitor; Control algorithm; Insulin pump; Review; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

AGE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DIABETES CONTROL; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; GLUCOSE SENSOR; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MOBILE PHONE; OUTPATIENT; PRIORITY JOURNAL; REMOTE SENSING; REVIEW; ALGORITHM; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL;

ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; PANCREAS, ARTIFICIAL;

EID: 84976478311     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4022-4     Document Type: Review

References (97)

1. Clarke SF, Foster JR (2012) A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci 69:83–93
2. Pickup JC, Keen H, Parsons JA, Alberti KG (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1:204–207
3. Tamborlane WV, Sherwin RS, Genel M, Felig P (1979) Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 300:573–578
4. Pickup JC (2012) Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol 8:425–433
5. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO (1999) Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA 282:1839–1844
6. Garg SK, Potts RO, Ackerman NR, Fermi SJ, Tamada JA, Chase HP (1999) Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 22:1708–1714
7. Rodbard D (2016) Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther 18(Suppl 2):S23–S213
8. Thabit H, Tauschmann M, Allen JM et al (2015) Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 373:2129–2140
9. Peyser T, Dassau E, Breton M, Skyler JS (2014) The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci 1311:102–123
10. Hovorka R (2011) Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 7:385–395
11. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW (2013) Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 310:1240–1247
12. Bergenstal RM, Klonoff DC, Garg SK et al (2013) Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 369:224–232
13. Maahs DM, Calhoun P, Buckingham BA et al (2014) A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 37:1885–1891
14. Kropff J, DeVries JH (2016) Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects. Diabetes Technol Ther 18(Suppl 2):S2-53–S2-63
15. Thabit H, Hovorka R (2014) Bringing closed- loop home: recent advances in closed- loop insulin delivery. Curr Opin Endocrinol Diabetes Obes 21:95–101
16. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
17. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
18. Cryer PE (2008) The barrier of hypoglycemia in diabetes. Diabetes 57:3169–3176
19. Pickup JC, Sutton AJ (2008) Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 25:765–774
20. Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H et al (2014) Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol 2:553–561
21. Ruan Y, Thabit H, Leelarathna L et al (2016) Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Care 39:830–832
22. Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA (2015) Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care 38:1008–1015
23. Manohar C, Levine JA, Nandy DK et al (2012) The effect of walking on postprandial glycemic excursion in patients with type 1 diabetes and healthy people. Diabetes Care 35:2493–2499
24. Bally L, Zueger T, Buehler T et al (2016) Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study. Diabetologia 59:776–784
25. Brown SA, Jiang B, McElwee-Malloy M, Wakeman C, Breton MD (2015) Fluctuations of hyperglycemia and insulin sensitivity are linked to menstrual cycle phases in women with type 1 diabetes. J Diabetes Sci Technol 9:1192–1199
26. Wong JC, Neinstein AB, Spindler M, Adi S (2015) A minority of patients with type 1 diabetes routinely downloads and retrospectively reviews device data. Diabetes Technol Ther 17:555–562
27. Beck RW (2015) Downloading diabetes device data: empowering patients to download at home to achieve better outcomes. Diabetes Technol Ther 17:536–537
28. Simmons JH, Chen V, Miller KM et al (2013) Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry. Diabetes Care 36:3573–3577
29. Hovorka R (2015) Artificial pancreas project at Cambridge 2013. Diabet Med 32:987–992
30. Johnson SR, Cooper MN, Davis EA, Jones TW (2013) Hypoglycaemia, fear of hypoglycaemia and quality of life in children with Type 1 diabetes and their parents. Diabet Med 30:1126–1131
31. Brod M, Wolden M, Christensen T, Bushnell DM (2013) A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 15:546–557
32. van Bon AC, Brouwer TB, von Basum G, Hoekstra JB, DeVries JH (2011) Future acceptance of an artificial pancreas in adults with type 1 diabetes. Diabetes Technol Ther 13:731–736
33. Elleri D, Acerini CL, Allen JM et al (2010) Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes. Diabetes Technol Ther 12:35–39
34. Barnard KD, Pinsker JE, Oliver N, Astle A, Dassau E, Kerr D (2015) Future artificial pancreas technology for type 1 diabetes: what do users want? Diabetes Technol Ther 17:311–315
35. Wong JC, Foster NC, Maahs DM et al (2014) Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care 37:2702–2709
36. de Bock M, Cooper M, Retterath A et al (2016) Continuous glucose monitoring adherence: Lessons from a clinical trial to predict outpatient behavior. J Diabetes Sci Technol 10:627–632
37. Barnard KD, Wysocki T, Thabit H et al (2015) Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. Diabet Med 32:601–608
38. Ziegler C, Liberman A, Nimri R et al (2015) Reduced worries of hypoglycaemia, high satisfaction, and increased perceived ease of use after experiencing four nights of MD-Logic artificial pancreas at home (DREAM4). J Diabetes Res 2015:590308
39. Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AJ (2014) Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes 7:211–223
40. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC (1967) Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 61:827–837
41. Gruessner RW, Gruessner AC (2013) The current state of pancreas transplantation. Nat Rev Endocrinol 9:555–562
42. Gruessner AC, Gruessner RW (2012) Pancreas transplant outcomes for United States and non United States cases as reported to the United Network for Organ Sharing and the International Pancreas Transplant Registry as of December 2011. Clin Transpl:23-40
43. de Ferranti SD, de Boer IH, Fonseca V et al (2014) Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 37:2843–2863
44. Rudolph EN, Finger EB, Chandolias N, Kandaswamy R, Sutherland DE, Dunn TB (2015) Outcomes of pancreas retransplantation. Transplantation 99:367–374
45. Lakey JR, Burridge PW, Shapiro AM (2003) Technical aspects of islet preparation and transplantation. Transpl Int 16:613–632
46. Ryan EA, Paty BW, Senior PA et al (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069
47. Shapiro AM (2011) State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep 11:345–354
48. Phillip M, Battelino T, Atlas E et al (2013) Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 368:824–833
49. Russell SJ, El-Khatib FH, Sinha M et al (2014) Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 371:313–325
50. Leelarathna L, Nodale M, Allen JM et al (2013) Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems. Diabetes Technol Ther 15:143–149
51. Thabit H, Leelarathna L, Wilinska ME et al (2015) Accuracy of continuous glucose monitoring during three closed-loop home studies under free-living conditions. Diabetes Technol Ther 17:801–807
52. Bergenstal RM, Tamborlane WV, Ahmann A et al (2010) Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 363:311–320
53. Choudhary P, Olsen BS, Conget I, Welsh JB, Vorrink L, Shin JJ (2016) Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 18:288–291
54. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF (2006) Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 55:3344–3350
55. Hovorka R, Canonico V, Chassin LJ et al (2004) Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 25:905–920
56. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV (2008) Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31:934–939
57. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER (2010) A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2:27ra27
58. Haidar A, Elleri D, Kumareswaran K et al (2013) Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes. Diabetes Care 36:e173–e174
59. Home PD (2012) The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab 14:780–788
60. Garg SK, Voelmle M, Gottlieb PA (2010) Time lag characterization of two continuous glucose monitoring systems. Diabetes Res Clin Pract 87:348–353
61. Basu A, Dube S, Veettil S et al (2015) Time lag of glucose from intravascular to interstitial compartment in type 1 diabetes. J Diabetes Sci Technol 9:63–68
62. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 17:682–688
63. Setji TL, Hong BD, Feinglos MN (2015) Technosphere insulin: inhaled prandial insulin. Expert Opin Biol Ther:1-7
64. Zisser H, Dassau E, Lee JJ, Harvey RA, Bevier W, Doyle FJ (2015) Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol 9:564–572
65. El-Laboudi AH, Oliver N (2015) Towards a physiological prandial insulin profile: Enhancement of subcutaneously injected prandial insulin using local warming devices. Diabetes Ther 6:257–272
66. Wang X, Ioacara S, DeHennis A (2015) Long-term home study on nocturnal hypoglycemic alarms using a new fully implantable continuous glucose monitoring system in type 1 diabetes. Diabetes Technol Ther 17:780–786
67. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S (2015) The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther 17:787–794
68. Hajnsek M, Nacht B, Sax S, List EJ, Klimant I, Sinner F (2014) The single-port concept: combining optical glucose measurement with insulin infusion. Acta Diabetol 51:883–886
69. Del Favero S, Place J, Kropff J et al (2015) Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. Diabetes Obes Metab 17:468–476
70. Del Favero S, Bruttomesso D, Di Palma F et al (2014) First use of model predictive control in outpatient wearable artificial pancreas. Diabetes Care 37:1212–1215
71. Grosman B, Ilany J, Roy A et al (2016) Hybrid closed-loop insulin delivery in type 1 diabetes during supervised outpatient conditions. J Diabetes Sci Technol 10:708–731
72. Ly TT, Breton MD, Keith-Hynes P et al (2014) Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care 37:2310–2316
73. Ly TT, Roy A, Grosman B et al (2015) Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care 38:1205–1211
74. Kovatchev BP, Renard E, Cobelli C et al (2014) Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 37:1789–1796
75. Brown SA, Kovatchev BP, Breton MD et al (2015) Multinight “bedside” closed-loop control for patients with type 1 diabetes. Diabetes Technol Ther 17:203–209
76. Nimri R, Muller I, Atlas E et al (2014) MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 37:3025–3032
77. Leelarathna L, Dellweg S, Mader JK et al (2014) Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 37:1931–1937
78. Tauschmann M, Allen JM, Wilinska ME et al (2016) Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. doi:10.2337/dc15-2078
79. Kropff J, Del Favero S, Place J et al (2015) 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 3:939–947
80. Barnard KD, Wysocki T, Allen JM et al (2014) Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care 2:e000025. doi:10.1136/bmjdrc-2014-000025
81. Bakhtiani PA, Zhao LM, El Youssef J, Castle JR, Ward WK (2013) A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy. Diabetes Obes Metab 15:1065–1070
82. Haidar A, Smaoui MR, Legault L, Rabasa-Lhoret R (2016) The role of glucagon in the artificial pancreas. Lancet Diabetes Endocrinol 4:476–479
83. Russell SJ, Hillard MA, Balliro C et al (2016) Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol 4:233–243
84. Haidar A, Legault L, Matteau-Pelletier L et al (2015) Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 3:595–604
85. van Bon AC, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, Devries JH (2014) Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther 16:131–136
86. Steiner SS, Li M, Hauser R, Pohl R (2010) Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol 4:1332–1337
87. Jackson MA, Caputo N, Castle JR, David LL, Roberts CT, Ward WK (2012) Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas. Curr Diab Rep 12:705–710
88. Cryer PE (2012) Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039–1048
89. Weinzimer SA, Sherr JL, Cengiz E et al (2012) Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 35:1994–1999
90. Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA (2014) Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol 8:1011–1017
91. Kowalski A (2015) Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care 38:1036–1043
92. Trevitt S, Simpson S, Wood A (2015) Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 10:714–723
93. O’Keeffe DT, Maraka S, Basu A, Keith-Hynes P, Kudva YC (2015) Cybersecurity in artificial pancreas experiments. Diabetes Technol Ther 17:664–666
94. Dauber A, Corcia L, Safer J, Agus MS, Einis S, Steil GM (2013) Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial. Diabetes Care 36:222–227
95. Murphy HR, Elleri D, Allen JM et al (2011) Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 34:406–411
96. Leelarathna L, English SW, Thabit H et al (2013) Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Crit Care 17:R159
97. Thabit H, Hovorka R (2014) Glucose control in non-critically ill inpatients with diabetes: towards closed-loop. Diabetes Obes Metab 16:500–509